These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7780612)

  • 1. In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour.
    Linehan DC; Peoples GE; Hess DT; Summerhayes IC; Parikh AS; Goedegebuure PS; Eberlein TJ
    Surg Oncol; 1995 Feb; 4(1):41-9. PubMed ID: 7780612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
    Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
    Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu.
    Peiper M; Goedegebuure PS; Izbicki JR; Eberlein TJ
    Anticancer Res; 1999; 19(4A):2471-5. PubMed ID: 10470176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
    Linehan DC; Goedegebuure PS; Peoples GE; Rogers SO; Eberlein TJ
    J Immunol; 1995 Nov; 155(9):4486-91. PubMed ID: 7594611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers.
    Peoples GE; Yoshino I; Douville CC; Andrews JV; Goedegebuure PS; Eberlein TJ
    J Immunol; 1994 May; 152(10):4993-9. PubMed ID: 7909829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
    Baxevanis CN; Gritzapis AD; Tsitsilonis OE; Katsoulas HL; Papamichail M
    Int J Cancer; 2002 Apr; 98(6):864-72. PubMed ID: 11948464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
    Yoshino I; Peoples GE; Goedegebuure PS; Maziarz R; Eberlein TJ
    J Immunol; 1994 Mar; 152(5):2393-400. PubMed ID: 8133050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.
    Peoples GE; Goedegebuure PS; Smith R; Linehan DC; Yoshino I; Eberlein TJ
    Proc Natl Acad Sci U S A; 1995 Jan; 92(2):432-6. PubMed ID: 7831305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes.
    Kono K; Rongcun Y; Charo J; Ichihara F; Celis E; Sette A; Appella E; Sekikawa T; Matsumoto Y; Kiessling R
    Int J Cancer; 1998 Oct; 78(2):202-8. PubMed ID: 9754653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.
    Goedegebuure PS; Douville CC; Doherty JM; Linehan DC; Lee KY; Ganguly EK; Eberlein TJ
    Cell Immunol; 1997 Feb; 175(2):150-6. PubMed ID: 9023420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
    Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
    Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.
    Yoshino I; Goedegebuure PS; Peoples GE; Parikh AS; DiMaio JM; Lyerly HK; Gazdar AF; Eberlein TJ
    Cancer Res; 1994 Jul; 54(13):3387-90. PubMed ID: 7912166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro.
    Li G; Zeng Y; Chen X; Larmonier N; Sepassi M; Graner MW; Andreansky S; Brewer MA; Katsanis E
    Clin Exp Immunol; 2007 Apr; 148(1):136-45. PubMed ID: 17349014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
    Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
    Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas.
    Rongcun Y; Salazar-Onfray F; Charo J; Malmberg KJ; Evrin K; Maes H; Kono K; Hising C; Petersson M; Larsson O; Lan L; Appella E; Sette A; Celis E; Kiessling R
    J Immunol; 1999 Jul; 163(2):1037-44. PubMed ID: 10395702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
    Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
    Fisk B; Blevins TL; Wharton JT; Ioannides CG
    J Exp Med; 1995 Jun; 181(6):2109-17. PubMed ID: 7539040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals.
    Okugawa T; Ikuta Y; Takahashi Y; Obata H; Tanida K; Watanabe M; Imai S; Furugen R; Nagata Y; Toyoda N; Shiku H
    Eur J Immunol; 2000 Nov; 30(11):3338-46. PubMed ID: 11093150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes.
    Ikuta Y; Okugawa T; Furugen R; Nagata Y; Takahashi Y; Wang L; Ikeda H; Watanabe M; Imai S; Shiku H
    Int J Cancer; 2000 Aug; 87(4):553-8. PubMed ID: 10918197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer.
    Peoples GE; Goedegebuure PS; Andrews JV; Schoof DD; Eberlein TJ
    J Immunol; 1993 Nov; 151(10):5481-91. PubMed ID: 8228240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.